FIG 6.

FKBP12 binding is not sufficient for blocking EBV lytic activation. (A) Structures of FK506, rapamycin, and nonimmunosuppressive FK506 analogs FKN4 and FKAM. The newly added substituents in FKN4 and FKAM are blue. (B) Effects of FK506, FKN4, and FKAM on the activation of an NFAT-luciferase reporter gene stimulated with PMA and ionomycin in Jurkat T cells. (C) NFAT luciferase reporter gene competition assay in Jurkat T cells. (D) BX1-Akata cells were pretreated with tacrolimus and tacrolimus analogs FKAM and FKN4 using various doses for 1 h followed by induction with anti-IgG for 24 h. (E) GFP-positive cells were counted and compared with the number of GFP-positive cells in an untreated sample. ctrl, control.